WPDPF - WPD Pharmaceuticals inks IMP deal with CNS Pharmaceuticals

WPD Pharmaceuticals (WPDPF) has signed an agreement with CNS Pharmaceuticals (CNSP) to obtain Investigational Medicinal Product ((IMP)) for use in the planned clinical trials of Berubicin.Berubicin is a novel anthracycline candidate for the treatment of a number of serious oncology indications including Glioblastoma Multiforme ((GBM)).WPD plans to initiate both a multicenter Berubicin Phase 2 trial in adult GBM in the first half of 2021 and a multicenter pediatric malignant glioma Phase 1 clinical trial in 2021.CNS Pharmaceuticals has received Investigational New Drug ((IND)) approval from the U.S.FDA to proceed with their planned randomized and controlled Phase 2 trial of Berubicin in the treatment of adults with GBM who have failed first-line therapy, which is expected to commence in the first quarter of 2021.

For further details see:

WPD Pharmaceuticals inks IMP deal with CNS Pharmaceuticals